🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

24 recruiting trials

for Leukemia, Other

Halt Aging in Survivors of Blood Cancers NCT07292272NA1 site📍 Omaha University of Nebraska · Tests: Behavioral Coaching Intervention, Virtual Exercise Platform Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038Phase 1, Phase 265 sites📍 Boston📍 Hackensack📍 New Brunswick AstraZeneca · Tests: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy NCT03555851n/a1 site📍 Charlotte Wake Forest University Health Sciences · Tests: Cyclophosphamide, Specimen collection Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment NCT01087333n/a1 site📍 Bethesda National Cancer Institute (NCI) MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms NCT04282187Phase 21 site📍 Seattle University of Washington · Tests: Decitabine, Ruxolitinib, Fedratinib, Questionnaire Administration, Pacritinib Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression NCT07155226Phase 1, Phase 230 sites📍 Decatur📍 New York📍 Chapel Hill AstraZeneca · Tests: AZD3632, Posaconazole Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy NCT06930352Phase 21 site📍 Columbus Uma Borate · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies. NCT06812104Phase 117 sites📍 Kamogawa📍 Yoshida📍 Kurume Kyowa Kirin Co., Ltd. · Tests: KK2845_1, KK2845_2, KK2845_3, KK2845_4, KK2845_5 Hairy Cell Leukemia Patient Data Registry NCT02560883n/a8 sites📍 Miami📍 Miami Beach📍 Rochester Ohio State University Comprehensive Cancer Center More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL) NCT07705178NA1 site📍 Erlangen University of Erlangen-Nürnberg Medical School · Tests: QOL assessment, Neuropsychological, Spirometry, DLCO measurement, Echocardioraphy, MRI Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation NCT02074839Phase 130 sites📍 Birmingham📍 Phoenix📍 Duarte Institut de Recherches Internationales Servier · Tests: AG-120 A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies NCT07271667Phase 211 sites📍 Miami Beach📍 Rochester📍 Florham Park Curis, Inc. · Tests: Emavusertib, Zanubrutinib Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006Phase 1, Phase 26 sites📍 Aurora📍 Coral Gables📍 Eugene Nurix Therapeutics, Inc. · Tests: NX-5948, venetoclax, rituximab, obinutuzumab Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer NCT07046078Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy,… Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL NCT04494503Phase 1, Phase 218 sites📍 Beijing📍 Chongqing📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-2575, Rituximab, Ibrutinib Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) NCT03970096Phase 23 sites📍 Tampa📍 Pittsburgh📍 Seattle Fred Hutchinson Cancer Center · Tests: Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555Phase 1, Phase 2104 sites📍 Newport Beach📍 Palo Alto📍 Denver Sumitomo Pharma America, Inc. · Tests: Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA) 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome NCT03670966Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem … Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL NCT04215809Phase 19 sites📍 Duarte📍 Jacksonville📍 Boston Ascentage Pharma Group Inc. · Tests: Lisaftoclax Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy